Ganciclovir-sodium-BW-759-sodium-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?Agonists?ScreeningLibrarieswww.MedChemEGanciclovirsodiumCat.No.:HY-13637ACASNo.:107910-75-8Synonyms:BW759sodium;2'-Nor-2'-deoxyguanosinesodium分?式:C?H??N?NaO?分?量:279.23作?靶點(diǎn):CMV;HSV;Antibiotic;NucleosideAntimetabolite/Analog作?通路:Anti-infection;CellCycle/DNADamage儲(chǔ)存?式:4°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfrom

light)溶解性數(shù)據(jù)體外實(shí)驗(yàn)H2O:50mg/mL(179.06mM;Needultrasonic)DMSO:5mg/mL(17.91mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM3.5813mL17.9064mL35.8128mL5mM0.7163mL3.5813mL7.1626mL10mM0.3581mL1.7906mL3.5813mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存?式和期限。BIOLOGICALACTIVITY?物活性Ganciclovir(BW759)sodium?種核苷類似物和?服抗病毒藥物，對(duì)CMV具有抗病毒活性。Ganciclovirsodium在體外對(duì)疹病毒(herpesgroup)和其他?些DNA病毒也具有抗病毒活性。Ganciclovirsodium抑制?類疹病毒(HSV1型和2型，CMV)和腺病毒?型1、2、4、6、8、10、19、22和28的體外復(fù)制。Ganciclovir對(duì)貓1型疹病毒(FHV-1)的IC50為5.2μM。IC50&TargetCMVHSV-1HSV-2FHV-11/2MasterofSmallMolecules—您?邊的抑制劑?師www.MedChemE5.2μM(IC50)體外研究GanciclovirsodiumisanacyclicdeoxyguanosineanalogstructurallysimilartoacyclovirbutwithsuperioractivityagainstCMV.Themedianganciclovirconcentrationrequiredtoinhibitviralreplicationby50percentis2.15mumolversus72mumolforacyclovir[4].TheprimarymechanismofgancicloviractionagainstCMVisinhibitionofthereplicationofviralDNAbyganciclovir-5'-triphosphate(ganciclovir-TP).ThisinhibitionincludesaselectiveandpotentinhibitionoftheviralDNApolymerase.Ganciclovirsodiumismetabolizedtothetriphosphateformbyprimarilythreecellularenzymes:adeoxyguanosinekinaseinducedbyCMV-infectedcells;guanylatekinase;andphosphoglyceratekinase[5].體內(nèi)研究Ganciclovirsodium(1-80mg/kg;i.h.;dailyfor5days)delaysMCMV-inducedwastingsyndromeandmortality[6].AnimalModel:Severecombinedimmunodeficiency(SCID)mice(MCMVinfection)[6]Dosage:1-80mg/kgAdministration:I.h.;dailyfor5daysResult:DosedependentlydelayedMCMV-inducedwastingsyndromeandmortality.?BrainBehavImmun.2019Aug;80:394-405.?JVirol.2017Jan18;91(3).pii:e02152-16.?EurJPharmSci.2019Jan15;127:29-37.?PharmacolResPerspect.2020Apr;8(2):e00575.?bioRxiv.2019Oct.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].MaggsDJ,etal.Invitroefficacyofganciclovir,cidofovir,penciclovir,foscarnet,idoxuridine,andacycloviragainstfelineherpesvirustype-1.AmJVetRes.2004Apr;65(4):399-403.[2].FauldsD,etal.Ganciclovir.Areviewofitsantiviralactivity,pharmacokineticpropertiesandtherapeuticefficacyincytomegalovirusinfections.Drugs.1990;39(4):597-638.[3].BoujemlaI,etal.Pharmacokineticsandtissuediffusionofganciclovirinmiceandrats.AntiviralRes.2016;132:111-115.[4].FletcherCV,etal.Evaluationofganciclovirforcytomegalovirusdisease.DICP.1989Jan;23(1):5-12.[5].MatthewsT,etal.Antiviralactivityandmechanismofactionofganciclovir.RevInfectDis.1988Jul-Aug;10Suppl3:S490-4.[6].DuanJ,ParisW,KiblerP,BousquetC,LiuzziM,CordingleyMG.Doseandduration-dependenceofganciclovirtreatmentagainstmurinecytomegalovirusinfectioninseverecombinedimmunodeficientmice.AntiviralRes.1998;39(3):189-197.McePdfHeight2/2MasterofSmallMolecules—您?邊的抑制劑?師www.MedChemECaution:Producthasnot